Introduction
Immunotactoid glomerulopathy (ITG), fi rst reported by Korbet et al. in 1985 as a glomerular deposition disease in which immunoglobulin-derived protein fi laments deposit in the glomeruli and cause a range of nephritis [1] , is a rare renal disease found in fewer than 1% of all kidney biopsies [2, 3] . It exhibits pathological manifestations ranging from mesangial proliferative glomerulonephritis to membranoproliferative glomerulonephritis (MPGN). Immunostaining is frequently positive for immunoglobulin G (IgG) κ or λ light chains and complement C3. Different from amyloidosis, Congo red staining is negative in ITG [4] . Although some patients reportedly respond to steroid therapy [5] , the treatment is ineffective in up to half of all cases. These patients develop end-stage renal failure within a few years after onset.
Few reports of kidney transplantation have been made for patients with ITG. Although ITG has a high rate of recurrence after kidney transplantation, loss of graft function reportedly progresses slowly. Some reports describe successful long-term graft survival after treatment for ITG recurrence. Therefore, kidney transplantation was not contraindicated for ITG [6] .
Our patient with ITG experienced immediate recurrence after kidney transplantation. His recurrent ITG did not respond
Abstract
We report a case of rapid recurrence of immunotactoid glomerulopathy (ITG) with monoclonal IgG3κ deposits in a transplanted renal graft. A 55-year-old hemodialysis male patient due to ITG underwent an ABO-incompatible living-donor kidney transplantation. Proteinuria (3.11 g/day) and increased serum creatinine (2.52 mg/dL) were detected on postoperative day (POD) 4 due to acute antibody-mediated rejection (aAMR). Even after treatment for aAMR, proteinuria increased again to 4.5 g/day because of a recurrent ITG with IgG3κ subclass deposits. He returned to maintenance hemodialysis 9 months after transplantation.
This case underlines the importance of preoperative monoclonal paraproteinuria test to predict an ITG recurrence in the renal graft.
to steroid pulse therapy. Although plasmapheresis was effective initially, renal function deteriorated gradually and maintenance hemodialysis started 9 months after transplantation. We herein report the clinical course of this case and review the relevant literature. Although the biopsy showed aAMR and electron deposition, the latter of which suggested ITG recurrence, the main cause of elevation of s-Cr level was regarded as a result of aAMR at that time.
Case Report
On POD 22, the s-Cr level increased again. A second renal biopsy was performed, the diagnosis of which was ITG recurrence. MPGN-like appearance was detected using light 
Discussion
This rare disease, ITG that is found in fewer than 1% of all kidney biopsies has characteristic electron-dense deposits with a microtubular structure in the glomeruli visualized using electron microscopy, but appearing negative with Congo red staining [2] . Actually, ITG can be distinguished pathologically from other types of glomerulopathies accompanied with fi brillary deposits, such as fi brillary gromerulonephritis, lupus nephritis, cryoglobulinemia and light-chain deposition disease. The deposits in ITG appear as hollow, regularly arranged microtubulars, with diameter greater than 30 nm [7] .
Clinically, ITG can engender proteinuria (often in the nephrotic range), microscopic hematuria and often hypertension, which might result in end stage renal disease necessitating renal replacement therapy in the long run [2] .
ITG and other deposition diseases are well known for their frequent recurrences after KTx [8] . Although the rate of ITG recurrence is as high as 47-64% [7, 9] , kidney transplantation in patients with ITG is not contraindicated because of the presence of successful cases [10] .
Korbet et al. reported a successful case of KTx for ITG [10] .
Azathioprine, prednisolone and anti-lymphocytoglobulin were used as immunosuppressive agents. The graft function was stable for about fi ve years with no recurrence. Neither monoclonal proteinemia nor hypocomplementemia was detected. In the other three cases, ITG recurred within 1.5-19 months [11] [12] [13] . Prednisolone, cyclosporine, azathioprine, tacrolimus, mycophenolate mofetil and thymoglobulins were administered as immunosuppressants. Prednisolone pulse therapy, cyclophosphamide, rituximab and plasma exchange were added as treatment for recurrence. After these therapies, each graft function recovered and lasted more than 1 year.
Neither monoclonal proteinemia nor hypocomplementemia was detected in these cases.
Korbet et al. reported another case which resulted in graft loss [10] . In this case, ITG recurred about 4.5 years after transplantation. Although the treatment for recurrence was initially effective, the graft function deteriorated gradually within a year, with no evidence of monoclonal proteinemia or of hypocomplementemia. Although immunostaining was positive for IgG, λ, κ and C3 IgG subclass were not described in their report.
In our case, ITG recurred within a month and caused graft loss at the earliest timing after transplant when compared with previous reports, i.e. only 9 months after transplantation.
Comparison to other cases [11] [12] [13] [14] , revealed that IgG3 subclass and hypocomplementemia were detected only in our case (Table 1 ). Although no report described the association between IgG subclasses and ITG recurrence, IgG3 subclass is well known to have strong affi nity for complement and inducement of its activation [15] . The cause of this rapid recurrence might be the presence of monoclonal paraproteinuria which sometimes indicates the activity of ITG, and associated with an activity of ITG at the time of transplantation. Since complications of ITG are localized only in kidneys, detecting activity of ITG is diffi cult to know especially in ESRD patients.
The treatment for ITG recurrence after KTx has not been determined. Plasmapheresis, steroids, cyclophosphamide, mycophenolate mofetil (MMF) and RXM have been reported to be effective for the treatment of recurrence of ITG in previous case studies [11] [12] [13] [14] . Steroid pulse therapy and plasmapheresis were tried in our case, with no good result. In addition, RXM, which had been effective for a previous case, was administered just before transplantation in this case and it could not prevent ITG recurrence.
Retrospectively speaking, the presence of monoclonal proteinemia and hypocomplementemia should have been evaluated before transplantation. Further preoperative treatment, including plasmaphereses, should be considered in cases when they were detected.
In conclusion, our case demonstrated the presence of rapid and refractory recurrence of ITG in the renal graft in which almost all treatments for antibody-mediated rejection were ineffective. Our experience suggests that monoclonal paraproteinuria might play an important role in the early recurrence of ITG. Additionally, IgG subclass tests might also be useful for making a prognosis of ITG recurrence, especially a rapidly progressive one. Further studies should be conducted to verify the fi ndings reported herein. 
